BioLineRx’s immunotherapy candidate AGI-134 shows positive effect in preclinical melanoma studies; shares ahead 8 … – Seeking Alpha
|
BioLineRx's immunotherapy candidate AGI-134 shows positive effect in preclinical melanoma studies; shares ahead 8 …
Seeking Alpha BioLineRx (NASDAQ:BLRX) is up 8% premarket on light volume in response to its announcement of positive results from preclinical studies assessing immunotherapy candidate AGI-134. The data will be presented at the ASCO-SITC Clinical Immuno-Oncology … BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical … |
